ImmuCell Corporation Interest Expense Nonoperating
ImmuCell Corporation (ICCC) reported Interest Expense Nonoperating of $95.67 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-13
- ImmuCell Corporation interest expense nonoperating for the quarter ending 2026-06-30 was $95.67K, a 23.34% decline year-over-year.
- ImmuCell Corporation interest expense nonoperating for the quarter ending 2026-03-31 was $99.67K, a 22.09% decline year-over-year.
- ImmuCell Corporation interest expense nonoperating for the quarter ending 2025-12-31 was $106.14K, a 22.06% decline year-over-year.
- ImmuCell Corporation interest expense nonoperating for the quarter ending 2025-09-30 was $134.52K, a 6.68% decline year-over-year.
- ImmuCell Corporation interest expense nonoperating for fiscal 2025 was $493.38K, a 13.25% decline from fiscal 2024.
- ImmuCell Corporation interest expense nonoperating for fiscal 2024 was $568.73K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $95.67K 10-Q · filed 2026-08-13 | $195.34K 10-Q · filed 2026-08-13 | $301.49K derived: sum of 3 quarters · filed 2026-08-13 | $436.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $99.67K 10-Q · filed 2026-05-14 | $205.82K derived: sum of 2 quarters · filed 2026-05-14 | $340.34K derived: sum of 3 quarters · filed 2026-05-14 | $465.13K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $106.14K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $240.66K derived: sum of 2 quarters · filed 2026-03-30 | $365.46K derived: sum of 3 quarters · filed 2026-08-13 | $493.38K 10-K · filed 2026-03-30 |
| 2025-09-30 | $134.52K 10-Q · filed 2025-11-13 | $259.31K derived: sum of 2 quarters · filed 2026-08-13 | $387.24K 10-Q · filed 2025-11-13 | $523.43K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $124.80K 10-Q · filed 2026-08-13 | $252.72K 10-Q · filed 2026-08-13 | $388.92K derived: sum of 3 quarters · filed 2026-08-13 | $533.06K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $127.93K 10-Q · filed 2026-05-14 | $264.12K derived: sum of 2 quarters · filed 2026-05-14 | $408.26K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $136.20K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $280.34K derived: sum of 2 quarters · filed 2026-03-30 | $568.73K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $144.14K 10-Q · filed 2025-11-13 | $432.53K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |